629 results on '"Dueñas-González, A."'
Search Results
2. Capítulo 25. El modelo del desarrollo de dimensiones que explican los obstáculos de las mujeres universitarias de la Universidad Tecnológica Linares en Linares, Nuevo León, México, que dirigen una Micro y Pequeña empresa en Linares.
- Author
-
Dueñas González, Melissa, primary, Parra Ramos, Guianeya Miganlay, additional, and Aguirre Garza, Jesús Gerardo, additional
- Published
- 2024
- Full Text
- View/download PDF
3. N-(2-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Induces Apoptosis and Cell Cycle Arrest in Breast Cancer Cells, Decreasing GPER Expression
- Author
-
Berenice Prestegui Martel, Alma Delia Chávez-Blanco, Guadalupe Domínguez-Gómez, Alfonso Dueñas González, Patricia Gaona-Aguas, Raúl Flores-Mejía, Selma Alin Somilleda-Ventura, Octavio Rodríguez-Cortes, Rocío Morales-Bárcena, Alberto Martínez Muñoz, Cesar Miguel Mejia Barradas, Jessica Elena Mendieta Wejebe, and José Correa Basurto
- Subjects
breast cancer ,apoptosis ,HDAC8 ,GPER ,triple-negative breast cancer ,cell line ,Organic chemistry ,QD241-441 - Abstract
In this work, we performed anti-proliferative assays for the compound N-(2-hydroxyphenyl)-2-propylpentanamide (HO-AAVPA) on breast cancer (BC) cells (MCF-7, SKBR3, and triple-negative BC (TNBC) MDA-MB-231 cells) to explore its pharmacological mechanism regarding the type of cell death associated with G protein-coupled estrogen receptor (GPER) expression. The results show that HO-AAVPA induces cell apoptosis at 5 h or 48 h in either estrogen-dependent (MCF-7) or -independent BC cells (SKBR3 and MDA-MB-231). At 5 h, the apoptosis rate for MCF-7 cells was 68.4% and that for MDA-MB-231 cells was 56.1%; at 48 h, that for SKBR3 was 61.6%, that for MCF-7 cells was 54.9%, and that for MDA-MB-231 (TNBC) was 43.1%. HO-AAVPA increased the S phase in MCF-7 cells and reduced the G2/M phase in MCF-7 and MDA-MB-231 cells. GPER expression decreased more than VPA in the presence of HO-AAVPA. In conclusion, the effects of HO-AAVPA on cell apoptosis could be modulated by epigenetic effects through a decrease in GPER expression.
- Published
- 2024
- Full Text
- View/download PDF
4. Ivermectin: Potential Repurposing of a Versatile Antiparasitic as a Novel Anticancer
- Author
-
Dueñas-González, Alfonso, primary and Juárez-Rodríguez, Mandy, additional
- Published
- 2022
- Full Text
- View/download PDF
5. N -(2-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Induces Apoptosis and Cell Cycle Arrest in Breast Cancer Cells, Decreasing GPER Expression.
- Author
-
Prestegui Martel, Berenice, Chávez-Blanco, Alma Delia, Domínguez-Gómez, Guadalupe, Dueñas González, Alfonso, Gaona-Aguas, Patricia, Flores-Mejía, Raúl, Somilleda-Ventura, Selma Alin, Rodríguez-Cortes, Octavio, Morales-Bárcena, Rocío, Martínez Muñoz, Alberto, Mejia Barradas, Cesar Miguel, Mendieta Wejebe, Jessica Elena, and Correa Basurto, José
- Subjects
TRIPLE-negative breast cancer ,G protein coupled receptors ,CELL cycle ,BREAST cancer ,CELL death - Abstract
In this work, we performed anti-proliferative assays for the compound N-(2-hydroxyphenyl)-2-propylpentanamide (HO-AAVPA) on breast cancer (BC) cells (MCF-7, SKBR3, and triple-negative BC (TNBC) MDA-MB-231 cells) to explore its pharmacological mechanism regarding the type of cell death associated with G protein-coupled estrogen receptor (GPER) expression. The results show that HO-AAVPA induces cell apoptosis at 5 h or 48 h in either estrogen-dependent (MCF-7) or -independent BC cells (SKBR3 and MDA-MB-231). At 5 h, the apoptosis rate for MCF-7 cells was 68.4% and that for MDA-MB-231 cells was 56.1%; at 48 h, that for SKBR3 was 61.6%, that for MCF-7 cells was 54.9%, and that for MDA-MB-231 (TNBC) was 43.1%. HO-AAVPA increased the S phase in MCF-7 cells and reduced the G2/M phase in MCF-7 and MDA-MB-231 cells. GPER expression decreased more than VPA in the presence of HO-AAVPA. In conclusion, the effects of HO-AAVPA on cell apoptosis could be modulated by epigenetic effects through a decrease in GPER expression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Hereditary Diffuse Gastric Cancer (HDGC). An overview.
- Author
-
Taja-Chayeb, L, Vidal-Millán, S, Trejo-Becerril, C, Pérez-Cárdenas, E, Chávez-Blanco, A, Domínguez-Gómez, G, González-Fierro, A, Romo-Pérez, A, and Dueñas-González, A
- Published
- 2021
- Full Text
- View/download PDF
7. Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]
- Author
-
Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, Chanona-Vilchis J, Chávez-Blanco A, Domínguez-Gómez G, Langley E, García-Carrancá A, and Dueñas-González A
- Subjects
hydralazine ,valproic acid ,epigenetics ,metastasis ,ras ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, et al. Onco Targets Ther. 2018;11:8823–8833. The authors have advised that an error during the preparation of the slide images for Figure 2C, on page 8827, led to the inadvertent duplication of features on the HV slide. All the original data was retained and the correct image for the HV treated chamber was used as a replacement. The correct Figure 2 is shown in Download Article.
- Published
- 2022
8. The non-vesicle extracellular DNA induces cell transformation associated with horizontal DNA transfer
- Author
-
Cruz-Sigüenza, DA De La, primary, Reyes-Grajeda, JP, additional, Velasco-Velázquez, MA, additional, Trejo-Becerril, Catalina, additional, Pérez-Cárdenas, Enrique, additional, Chávez-Blanco, Alma Delia, additional, Taja-Chayeb, Lucía, additional, Domínguez-Gómez, Guadalupe, additional, Ramos-Godinez, Pilar, additional, González-Fierro, Aurora, additional, and Dueñas-González, Alfonso, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
- Author
-
Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, Chanona-Vilchis J, Chávez-Blanco A, Domínguez-Gómez G, Langley E, García-Carrancá A, and Dueñas-González A
- Subjects
Hydralazine ,valproic acid ,epigenetics ,metastasis ,ras ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Enrique Pérez-Cárdenas,1 Lucía Taja-Chayeb,1 Catalina Trejo-Becerril,1 José Chanona-Vilchis,2 Alma Chávez-Blanco,1 Guadalupe Domínguez-Gómez,1 Elizabeth Langley,1 Alejandro García-Carrancá,3,4 Alfonso Dueñas-González3,4 1Division of Basic Research, Instituto Nacional de Cancerología, Mexico City, Mexico; 2Department of Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico; 3Unit of Biomedical Research on Cancer, Biomedical Research Institute, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico; 4Unit of Biomedical Research on Cancer, Instituto Nacional de Cancerologia, Mexico City, Mexico Introduction: Metastasis involves the accumulation of genetic and epigenetic alterations leading to activation of prometastatic genes and inactivation of antimetastatic genes. Among epigenetic alterations, DNA hypermethylation and histone hypoacetylation are the focus of intense translational research because their pharmacological inhibition has been shown to produce antineoplastic activity in a variety of experimental models. Aims: This study aimed to evaluate the antimetastatic effect of the DNA-methylation inhibitor, hydralazine, and the histone deacetylase inhibitor, valproic acid. Methods: NIH 3T3-Ras murine cells were treated with hydralazine and valproic acid to evaluate their effects upon cell proliferation, cell motility, chemotaxis, gelatinase activity, and gene expression. Lung metastases were developed by intravenous injection of NIH 3T3-Ras cells in BALB/c nu/nu mice and then treated with the drug combination. Results: Treatment induced a growth-inhibitory effect on NIH 3T3-Ras cells, showed a trend toward increased gelatinase activity of MMP2 and MMP9, and inhibited chemotaxis and cell motility. The combination led to a strong antimetastatic effect in lungs of nude mice. Conclusion: Hydralazine and valproic acid, two repositioned drugs as epigenetic agents, exhibit antimetastatic effects in vitro and in vivo and hold potential for cancer treatment. Keywords: hydralazine, valproic acid, epigenetics, metastasis, ras
- Published
- 2018
10. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
- Author
-
Luis F. Oñate-Ocaña, Mayra Ponce-Martínez, Lucia Taja-Chayeb, Olga Gutiérrez-Hernández, Alejandro Avilés-Salas, David Cantú-de-León, Alfonso Dueñas-González, and Myrna Candelaria-Hernández
- Subjects
EZH2 mutations. Diffuse large B-cell lymphoma. Progression-free survival. Overall survival. Cohort study. ,Internal medicine ,RC31-1245 - Abstract
Background: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. Methods: In a cohort of patients with DLBCL treated between 2015 and 2017, we analyzed the presence of EZH2 mutations and their association with clinical response (CR), relapse, progression-free survival (PFS), and overall survival (OS). Results: A total of 198 patients were included; of them, 30 (15.2%) had mutations at codon 641, in exon 16 of EZH2. Response was achieved in 151 patients (76.3%), and 43 (21.7%) relapsed or progressed during follow-up. EZH2 mutations were associated with relapse/progression (risk ratio [RR] 1.18; 95% confidence interval [CI] 0.98–1.42; p = 0.031), while a trend for not achieving a complete response was observed (RR: 0.876; 95%CI 0.74–1.038; p = 0.071). Of note, Tyr641His and Tyr641Ser EZH2 mutations were associated with shorter PFS (hazard ratio 3.234; 95% CI 1.149–9.1; p = 0.026). Conclusion: The presence of EZH2 mutations was negatively associated with relapse/progression and showed a trend for lack of complete response. Further studies are needed to define better the prognostic significance of these mutations in Mexican-Mestizo DLBCL patients.
- Published
- 2021
- Full Text
- View/download PDF
11. Advancing clinical research globally: Cervical cancer research network from Mexico
- Author
-
Ager, Bryan J., Gallardo-Rincón, Dolores, de León, David Cantú, Chávez-Blanco, Adriana, Chuang, Linus, Dueñas-González, Alfonso, Gómez-García, Eva, Jerez, Roberto, Jhingran, Anuja, McCormack, Mary, Mileshkin, Linda, Pérez-Plasencia, Carlos, Plante, Marie, Poveda, Andrés, and Gaffney, David K.
- Published
- 2018
- Full Text
- View/download PDF
12. Ultrasound, histopathological, and genetic features of uveal melanoma in a Mexican-Mestizo population
- Author
-
Delgado, S., Rodriguez Reyes, A., Mora Rios, L., Dueñas-González, A., Taja-Chayeb, L., and Moragrega Adame, E.
- Published
- 2018
- Full Text
- View/download PDF
13. Características ultrasonográficas, histopatológicas y genéticas del melanoma uveal en población mexicana mestiza☆
- Author
-
Delgado, S., Rodriguez Reyes, A., Mora Rios, L., Dueñas-González, A., Taja-Chayeb, L., and Moragrega Adame, E.
- Published
- 2018
- Full Text
- View/download PDF
14. Advancing clinical research globally: Cervical cancer research network from Mexico
- Author
-
Bryan J. Ager, Dolores Gallardo-Rincón, David Cantú de León, Adriana Chávez-Blanco, Linus Chuang, Alfonso Dueñas-González, Eva Gómez-García, Roberto Jerez, Anuja Jhingran, Mary McCormack, Linda Mileshkin, Carlos Pérez-Plasencia, Marie Plante, Andrés Poveda, and David K. Gaffney
- Subjects
Gynecology and obstetrics ,RG1-991 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Cervical cancer is the fourth most common cancer in women with 85% of the mortality burden occurring in less-developed regions of the world. The Cervix Cancer Research Network (CCRN) was founded by the Gynecologic Cancer InterGroup (GCIG) with a mission to improve outcomes in cervix cancer by increasing access to high-quality clinical trials worldwide, with particular attention to less-developed, underrepresented sites. The CCRN held its second international educational symposium in Mexico City with ninety participants from fifteen Latin America countries in January 2017. The purpose of this symposium was to advance knowledge in cervix cancer therapy, promote recruitment to CCRN clinical trials, and to identify relevant future CCRN clinical trial concepts that could improve global care standards for women with cervical cancer. Keywords: Cervix cancer, Cervical cancer, Radiotherapy, CCRN, Hypofractionation
- Published
- 2018
- Full Text
- View/download PDF
15. Mild C(sp3)–H functionalization of dihydrosanguinarine and dihydrochelerythrine for development of highly cytotoxic derivatives
- Author
-
Romo-Pérez, Adriana, Miranda, Luis Demetrio, Chávez-Blanco, Alma D., Dueñas-González, Alfonso, Camacho-Corona, María del Rayo, Acosta-Huerta, Alejandrina, and García, Abraham
- Published
- 2017
- Full Text
- View/download PDF
16. Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region
- Author
-
Martínez-Mesa, J., Werutsky, G., Michiels, S., Pereira Filho, C.A.S., Dueñas-González, A., Zarba, J.J., Mano, M., Villarreal-Garza, C., Gómez, H., and Barrios, C.H.
- Published
- 2017
- Full Text
- View/download PDF
17. Modifications on the Tetrahydroquinoline Scaffold Targeting a Phenylalanine Cluster on GPER as Antiproliferative Compounds against Renal, Liver and Pancreatic Cancer Cells
- Author
-
David Méndez-Luna, Loreley Araceli Morelos-Garnica, Juan Benjamín García-Vázquez, Martiniano Bello, Itzia Irene Padilla-Martínez, Manuel Jonathan Fragoso-Vázquez, Alfonso Dueñas González, Nuria De Pedro, José Antonio Gómez-Vidal, Humberto Lubriel Mendoza-Figueroa, and José Correa-Basurto
- Subjects
GPER ,docking ,molecular dynamics simulations ,Suzuki–Miyaura cross-coupling ,tetrahydroquinoline scaffold ,antiproliferative ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
The implementation of chemo- and bioinformatics tools is a crucial step in the design of structure-based drugs, enabling the identification of more specific and effective molecules against cancer without side effects. In this study, three new compounds were designed and synthesized with suitable absorption, distribution, metabolism, excretion and toxicity (ADME-tox) properties and high affinity for the G protein-coupled estrogen receptor (GPER) binding site by in silico methods, which correlated with the growth inhibitory activity tested in a cluster of cancer cell lines. Docking and molecular dynamics (MD) simulations accompanied by a molecular mechanics/generalized Born surface area (MMGBSA) approach yielded the binding modes and energetic features of the proposed compounds on GPER. These in silico studies showed that the compounds reached the GPER binding site, establishing interactions with a phenylalanine cluster (F206, F208 and F278) required for GPER molecular recognition of its agonist and antagonist ligands. Finally, a 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay showed growth inhibitory activity of compounds 4, 5 and 7 in three different cancer cell lines—MIA Paca-2, RCC4-VA and Hep G2—at micromolar concentrations. These new molecules with specific chemical modifications of the GPER pharmacophore open up the possibility of generating new compounds capable of reaching the GPER binding site with potential growth inhibitory activities against nonconventional GPER cell models.
- Published
- 2021
- Full Text
- View/download PDF
18. Discovery and development of DNA methyltransferase inhibitors using in silico approaches
- Author
-
Medina-Franco, José L., Méndez-Lucio, Oscar, Dueñas-González, Alfonso, and Yoo, Jakyung
- Published
- 2015
- Full Text
- View/download PDF
19. The role of extracellular DNA (exDNA) in cellular processes
- Author
-
Enrique Pérez-Cárdenas, Ileana J Fernández-Domínguez, Catalina Trejo-Becerril, Joaquin Manzo-Merino, Alfonso Dueñas-González, and Lucia Taja-Chayeb
- Subjects
0301 basic medicine ,Pharmacology ,Cancer Research ,DNA ,Review ,Prognosis ,Extracellular dna ,Cell biology ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Oncology ,chemistry ,Neoplasms ,030220 oncology & carcinogenesis ,Humans ,Molecular Medicine - Abstract
Nowadays, extracellular DNA or circulating cell-free DNA is considered to be a molecule with clinical applications (diagnosis, prognosis, monitoring of treatment responses, or patient follow-up) in diverse pathologies, especially in cancer. Nevertheless, because of its molecular characteristics, it can have many other functions. This review focuses on the participation of extracellular DNA (exDNA) in fundamental processes such as cell signaling, coagulation, immunity, evolution through horizontal transfer of genetic information, and adaptive response to inflammatory processes. A deeper understanding of its role in each of these processes will allow development of better tools to monitor and control pathologies, as well as helping to generate new therapeutic options, beyond the applicability of DNA in liquid biopsy.
- Published
- 2021
20. Perspectives on Drug Repurposing
- Author
-
Daniel Juárez-López, Alejandro Schcolnik-Cabrera, and Alfonso Dueñas-González
- Subjects
Pharmacology ,0303 health sciences ,Government ,Drug Industry ,business.industry ,Organic Chemistry ,Drug Repositioning ,Investment (macroeconomics) ,01 natural sciences ,Biochemistry ,010101 applied mathematics ,Clinical trial ,03 medical and health sciences ,Biosafety ,Drug repositioning ,Risk analysis (engineering) ,SAFER ,Drug Discovery ,Humans ,Molecular Medicine ,0101 mathematics ,business ,Repurposing ,030304 developmental biology ,Pharmaceutical industry - Abstract
Complex common diseases are a significant burden for our societies and demand not only preventive measures but also more effective, safer, and more affordable treatments. The whole process of the current model of drug discovery and development implies a high investment by the pharmaceutical industry, which ultimately impact in high drug prices. In this sense, drug repurposing would help meet the needs of patients to access useful and novel treatments. Unlike the traditional approach, drug repurposing enters both the preclinical evaluation and clinical trials of the compound of interest faster, budgeting research and development costs, and limiting potential biosafety risks. The participation of government, society, and private investors is needed to secure the funds for experimental design and clinical development of repurposing candidates to have affordable, effective, and safe repurposed drugs. Moreover, extensive advertising of repurposing as a concept in the health community, could reduce prescribing bias when enough clinical evidence exists, which will support the employment of cheaper and more accessible repurposed compounds for common conditions.
- Published
- 2021
21. Drug repurposing for cancer therapy, easier said than done
- Author
-
Aurora Gonzalez-Fierro and Alfonso Dueñas-González
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Cancer drugs ,Cancer therapy ,Antineoplastic Agents ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,SAFER ,Drug Discovery ,Animals ,Humans ,Medicine ,Cancer biology ,Intensive care medicine ,Repurposing ,business.industry ,Drug Repositioning ,Cancer ,medicine.disease ,Drug repositioning ,ComputingMethodologies_PATTERNRECOGNITION ,030104 developmental biology ,030220 oncology & carcinogenesis ,business ,Standard therapy - Abstract
Drug repurposing for cancer therapy is currently a hot topic of research. Theoretically, in contrast to the known hurdles of developing new molecular entities, the approach of repurposing has several advantages. Mostly, it is said that it is faster, safer, easier, and cheaper. In the real world, however, there are only three repurposed drugs so far, that are listed in widely recognized cancer guidelines, but a large number of them are being studied. Among the many barriers to repurposing cancer drugs, economical-driven are the most important that difficult the clinical development of them. In this review, we provide an overview of the current status of drug repurposing for cancer therapy and the barriers that need to be overcome to realize the benefit of this approach. It means to have repositioned drugs for cancer therapy accepted as standard therapy for cancer indications at low cost.
- Published
- 2021
22. Hereditary diffuse gastric cancer (HDGC). An overview
- Author
-
Taja-Chayeb, L, primary, Vidal-Millán, S, additional, Trejo-Becerril, C, additional, Pérez-Cárdenas, E, additional, Chávez-Blanco, A, additional, Domínguez-Gómez, G, additional, González-Fierro, A, additional, Romo-Pérez, A, additional, and Dueñas-González, A, additional
- Published
- 2022
- Full Text
- View/download PDF
23. Planning cancer control in Latin America and the Caribbean
- Author
-
Goss, Paul E, Lee, Brittany L, Badovinac-Crnjevic, Tanja, Strasser-Weippl, Kathrin, Chavarri-Guerra, Yanin, Louis, Jessica St, Villarreal-Garza, Cynthia, Unger-Saldaña, Karla, Ferreyra, Mayra, Debiasi, Márcio, Liedke, Pedro ER, Touya, Diego, Werutsky, Gustavo, Higgins, Michaela, Fan, Lei, Vasconcelos, Claudia, Cazap, Eduardo, Vallejos, Carlos, Mohar, Alejandro, Knaul, Felicia, Arreola, Hector, Batura, Rekha, Luciani, Silvana, Sullivan, Richard, Finkelstein, Dianne, Simon, Sergio, Barrios, Carlos, Kightlinger, Rebecca, Gelrud, Andres, Bychkovsky, Vladimir, Lopes, Gilberto, Stefani, Stephen, Blaya, Marcelo, Souza, Fabiano Hahn, Santos, Franklin Santana, Kaemmerer, Alberto, de Azambuja, Evandro, Zorilla, Andres Felipe Cardona, Murillo, Raul, Jeronimo, Jose, Tsu, Vivien, Carvalho, Andre, Gil, Carlos Ferreira, Sternberg, Cinthya, Dueñas-Gonzalez, Alfonso, Sgroi, Dennis, Cuello, Mauricio, Fresco, Rodrigo, Reis, Rui Manuel, Masera, Guiseppe, Gabús, Raúl, Ribeiro, Raul, Knust, Renata, Ismael, Gustavo, Rosenblatt, Eduardo, Roth, Berta, Villa, Luisa, Solares, Argelia Lara, Leon, Marta Ximena, Torres-Vigil, Isabel, Covarrubias-Gomez, Alfredo, Hernández, Andrés, Bertolino, Mariela, Schwartsmann, Gilberto, Santillana, Sergio, Esteva, Francisco, Fein, Luis, Mano, Max, Gomez, Henry, Hurlbert, Marc, Durstine, Alessandra, and Azenha, Gustavo
- Published
- 2013
- Full Text
- View/download PDF
24. Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]
- Author
-
Enrique Pérez-Cárdenas, Lucía Taja-Chayeb, Catalina Trejo-Becerril, José Chanona-Vilchis, Alma Chávez-Blanco, Guadalupe Domínguez-Gómez, Elizabeth Langley, Alejandro García-Carrancá, and Alfonso Dueñas-González
- Subjects
Oncology ,Pharmacology (medical) ,OncoTargets and Therapy - Abstract
Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, et al. Onco Targets Ther. 2018;11:8823–8833. The authors have advised that an error during the preparation of the slide images for Figure 2C, on page 8827, led to the inadvertent duplication of features on the HV slide. All the original data was retained and the correct image for the HV treated chamber was used as a replacement. The correct Figure 2 is shown in Download Article.  
- Published
- 2022
25. Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial
- Author
-
Dueňas-González, A., Orlando, M., Zhou, Y., Quinlivan, M., and Barraclough, H.
- Published
- 2012
- Full Text
- View/download PDF
26. Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia
- Author
-
Cervera, Eduardo, Candelaria, Myrna, López-Navarro, Omar, Labardini, Juan, Gonzalez-Fierro, Aurora, Taja-Chayeb, Lucia, Cortes, Jorge, Gordillo-Bastidas, Daniela, and Dueñas-González, Alfonso
- Published
- 2012
- Full Text
- View/download PDF
27. Drug Repurposing for Epigenetic Targets Guided by Computational Methods
- Author
-
Naveja, J. Jesús, primary, Dueñas-González, Alfonso, additional, and Medina-Franco, José L., additional
- Published
- 2016
- Full Text
- View/download PDF
28. List of Contributors
- Author
-
Aguayo-Ortiz, Rodrigo, primary, Arimondo, Paola B., additional, Correa-Basurto, J., additional, Del Rio, Alberto, additional, Dueñas-González, Alfonso, additional, Erdmann, Alexandre, additional, Fernández-de Gortari, Eli, additional, George Zheng, Y., additional, González-Juárez, D.E., additional, Guianvarc’h, Dominique, additional, Jung, Manfred, additional, Karaman, Berin, additional, Kireev, Dmitri, additional, Luo, Cheng, additional, Lu, Wenchao, additional, Lu, Wencong, additional, Martinez-Mayorga, Karina, additional, Medina-Franco, José L., additional, Méndez-Lucio, Oscar, additional, Meng, Fanwang, additional, Miletić, Vedran, additional, Montes, Carolina Peña, additional, Naveja, J. Jesús, additional, Nikolić, Patrik, additional, Odorcić, Ivica, additional, Qian, Kun, additional, Ragno, Rino, additional, Sippl, Wolfgang, additional, Svedružić, Željko M., additional, Varchi, Greta, additional, Wang, Chen, additional, Wan, Wei, additional, Yoo, Jakyung, additional, and Zacarías-Lara, O.J., additional
- Published
- 2016
- Full Text
- View/download PDF
29. Introduction of Epigenetic Targets in Drug Discovery and Current Status of Epi-Drugs and Epi-Probes
- Author
-
Dueñas-González, Alfonso, primary, Jesús Naveja, J., additional, and Medina-Franco, José L., additional
- Published
- 2016
- Full Text
- View/download PDF
30. Language Ideologies
- Author
-
Roseann Dueñas González and Ildikó Melis
- Subjects
Movement (music) ,media_common.quotation_subject ,Political science ,Media studies ,Ideology ,media_common - Published
- 2021
31. Percepción de salud en adultos mayores de la provincia Matanzas Health perception in elderly persons from the Matanzas province
- Author
-
Dianelis María Dueñas González, Héctor Demetrio Bayarre Vea, Eduardo Alfredo Triana Álvarez, and Vivian Rodríguez Pérez
- Subjects
Adulto mayor ,calidad de vida ,salud percibida ,Elderly person ,quality of life ,perceived health ,Medicine (General) ,R5-920 - Abstract
Introducción: el estudio de la calidad de vida global y de sus dimensiones es de gran utilidad en los adultos mayores, en tanto constituye un trazador cualitativo de la salud en este segmento poblacional, aquejado con frecuencia de discapacidades que limitan su desempeño social. Objetivos: identificar la percepción de la dimensión salud por parte los adultos mayores de la provincia de Matanzas, y su relación con variables seleccionadas, durante el primer semestre de 2007. Métodos: se realizó un estudio descriptivo de corte transversal, en un universo de 108 559 adultos mayores, de los que se seleccionó una muestra de 741 a través de la fórmula de cálculo de tamaño de muestra para estudios descriptivos, elegida por muestreo estratificado polietápico. Para la recogida de la información se aplicaron el Examen Mínimo del Estado Mental y la Escala para la Evaluación de la Calidad de Vida Percibida. Se calcularon frecuencias absolutas y porcentajes, y se aplicó la prueba de homogeneidad y otras específicas como Ridit Analysis y X² para la regresión. El procesamiento se realizó con SPSS versión 11,5, y Epidat 3,1. Los resultados de presentan en cuadros estadísticos. Resultados: predominó la categoría alta de la dimensión salud con valores de 91,7 %, aunque en la medida que se incrementa la edad hay una disminución de la percepción alta de salud (p= 0,000). La percepción alta de salud es más marcada en los ancianos con pareja, con un 95,5 %, que en los que no tienen pareja (88,2 %) (p= 0,000). A pesar de que para todas las categorías de la variable escolaridad predominó la alta percepción de salud, existe una tendencia al incremento de esta, en la medida en que aumenta el nivel de escolaridad (p= 0,000). No hubo diferencias por sexo (p= 0,506). Conclusiones: la alta percepción de salud emitida por la población objeto de estudio se expresa de manera homogénea por sexos, pero heterogénea por grupos de edades, estado conyugal y escolaridad, lo cual evidencia la relación importante que existe entre estas últimas y la dimensión investigada.Introduction: the study of the global quality of life and of its dimensions is very useful in elderly persons since it is qualitative health marker in this population segment suffering frequently of inabilities limiting its social performance. Objectives: to identify the perception of health dimension by elderly persons from the Matanzas province and its relation to the variables selected during the first semester of 2007. Methods: a cross-sectional and descriptive study was conducted in 108 559 elderly persons selecting a sample including 714 by formula of sample size calculus for descriptive studies using multistage stratified sampling. To information collection the Minimal Examination of Mental Status and the Perceived Quality of Life Assessment were applied. Absolute and percentages frequencies were estimated applying the homogeneity test and other like Ridit Analysis and X² for regression. Processing was carried out with SPSS version 11,5 and Epidat 3,1. Results are showed in statistical charts. Results: there was predominance of high category in health dimension with values of 91,7 %, although just as an increase in age there is a decrease of high health perception (p= 0,000). The high health perception is more marked in elderly persons with a couple, with a 95,5 % than those without couple (88,2 %) (p= 0,000). In spite of the fact that for all the categories of schooling variable predominated the high health perception, there is a trend to its increase according to increases the schooling level. Conclusions: the high health perception declared by study population, it is expressed in a homogenous way by sexes, but like heterogeneous by age groups, marital condition and schooling level evidencing the significant relation between these latter and the study dimension.
- Published
- 2011
32. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
- Author
-
Oñate-Ocaña, Luis F., primary, Ponce-Martínez, Mayra, additional, Taja-Chayeb, Lucia, additional, Gutiérrez-Hernández, Olga, additional, Avilés-Salas, Alejandro, additional, Cantú-de-León, David, additional, Dueñas-González, Alfonso, additional, and Candelaria-Hernández, Myrna, additional
- Published
- 2021
- Full Text
- View/download PDF
33. Ivermectin: Potential Repurposing of a Versatile Antiparasitic as a Novel Anticancer
- Author
-
Alfonso Dueñas-González and Mandy Juárez-Rodríguez
- Subjects
Ivermectin ,business.industry ,Antiparasitic ,medicine.drug_class ,parasitic diseases ,Medicine ,Pharmacology ,business ,Repurposing ,medicine.drug - Abstract
Drug repositioning is a alternative strategy to discover and develop anticancer drugs based on identification of new mechanisms of actions and indications for existing compounds. Ivermectin belongs to the avermectin group of compounds, a series of 16-membered macrocyclic lactone moieties discovered in 1967 and FDA-approved for human use since 1987. Ivermectin has since been used by millions of people worldwide, and have demonstrated a wide margin of clinical safety. Here we summarize the in vitro and in vivo evidence demonstrating ivermectin\'s potential as a multitargeting anticancer drug that exerts antitumor effects against different tumor types. Notably, the in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically achieved based on human pharmacokinetic studies done in the clinical studies. Moreover, repurposed ivermectin safety has been well established recently in clinical studies against COVID-19. Consequently, we believe that ivermectin is an excellent potential candidate drug that can be repurposed for cancer and deserves rigorous evaluation against a variety of cancers in well-designed clinical trials.
- Published
- 2021
34. Global strategies for the treatment of early-stage and advanced cervical cancer
- Author
-
Dueñas-González, Alfonso and Campbell, Sergio
- Published
- 2016
- Full Text
- View/download PDF
35. List of Contributors
- Author
-
Bernstein, Alison I., primary, Biette, Kelly M., additional, Black, Joshua C., additional, Chatterjee, Champak, additional, Chen, Aili, additional, Chen, Xiangyun Amy, additional, Dhall, Abhinav, additional, Dueñas-González, Alfonso, additional, Fan, Yuhong, additional, Garcia, Benjamin A., additional, Han, Zhen, additional, Hauser, Alexander-Thomas, additional, Huang, Gang, additional, Huang, Kenneth, additional, Jin, Peng, additional, Jung, Manfred, additional, Kondengaden, Shukkoor, additional, Kornacki, James R., additional, Li, Haitao, additional, Li, Keqin Kathy, additional, Lu, Junyan, additional, Luan, Yepeng, additional, Luo, Cheng, additional, Luo, Minkui, additional, Masch, Antonia, additional, Medina-Franco, José L., additional, Mrksich, Milan, additional, Ngo, Liza, additional, Oyelere, Adegboyega K., additional, Pan, Chenyi, additional, Pradhan, Sriharsa, additional, Qing, Zhang, additional, Qu, Meihua, additional, Reimer, Ulf, additional, Reyhanfard, Hamed, additional, Roatsch, Martin, additional, Robaa, Dina, additional, Schulz-Fincke, Johannes, additional, Schutkowski, Mike, additional, Sidoli, Simone, additional, Sippl, Wolfgang, additional, Sodji, Quaovi H., additional, Sun, Jinquan, additional, Terragni, Jolyon, additional, Tian, Xiao-Jun, additional, Wang, Peng George, additional, Wang, Xiaoshi, additional, Wang, Xuejian, additional, Wang, Yanming, additional, Whetstine, Johnathan R., additional, Wooten, Jonathan, additional, Xing, Jianhua, additional, Xu, Wei, additional, Yoo, Jakyung, additional, Yu, Jin, additional, Zeng, Hao, additional, Zerweck, Johannes, additional, Zhai, Bingxue Chris, additional, Zhang, Hang, additional, Zhang, Hao, additional, Zhang, Liyi, additional, Zhang, Yunzhe, additional, Zhao, Shuai, additional, and Zheng, Y. George, additional
- Published
- 2015
- Full Text
- View/download PDF
36. DNA Methyltransferase Inhibitors for Cancer Therapy
- Author
-
Medina-Franco, José L., primary, Yoo, Jakyung, additional, and Dueñas-González, Alfonso, additional
- Published
- 2015
- Full Text
- View/download PDF
37. Hereditary diffuse gastric cancer (HDGC). An overview
- Author
-
Guadalupe Dominguez-Gomez, L Taja-Chayeb, Aurora Gonzalez-Fierro, Catalina Trejo-Becerril, S Vidal-Millán, Adriana Romo-Pérez, Alma Chavez-Blanco, Alfonso Dueñas-González, and Enrique Pérez-Cárdenas
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Family aggregation ,Cancer ,Disease ,Adenocarcinoma ,medicine.disease ,Malignancy ,Cadherins ,Germline mutation ,Stomach Neoplasms ,Internal medicine ,Mutation ,medicine ,Humans ,Genetic Predisposition to Disease ,Hereditary diffuse gastric cancer ,business ,Pathological ,Germ-Line Mutation ,Genetic testing - Abstract
It is estimated that up to 10% of gastric carcinomas show familial aggregation. In contrast, around 1-3 % (approximately 33,000 yearly) are genuinely hereditary. Hereditary diffuse gastric cancer (HDGC) is a rare malignancy characterized by autosomal dominant inheritance of pathological variants of the CDH1 and CTNNA1 genes encoding the adhesion molecules E-cadherin and α-catenin, respectively. The multifocal nature of the disease and the difficulty of visualizing precursor lesions by endoscopy underscore the need to be aware of this malignancy as surgical prevention can be fully protective. Here, we provide an overview of the main epidemiological, clinical, genetic, and pathological features of HDGC, as well as updated guidelines for its diagnosis, genetic testing, counseling, surveillance, and management. We conclude that HDGC is a rare, highly penetrant disease that is difficult to diagnose and manage, so it is necessary to correctly identify it to offer patients and their families’ adequate management following the recommendations of the IGCL. A critical point is identifying a mutation in HDGC families to determine whether unaffected relatives are at risk for cancer.
- Published
- 2021
38. BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal
- Author
-
Adriana Romo-Pérez, Guadalupe Domínguez-Gómez, Lucia Taja-Chayeb, Aurora Gonzalez-Fierro, Alfonso Dueñas-González, Elisa Garcia Martinez, José Correa-Basurto, and Alma Chavez-Blanco
- Subjects
Drug ,Simvastatin ,Apomorphine ,business.industry ,media_common.quotation_subject ,Trimetazidine ,Cancer ,General Medicine ,Disease ,Pharmacology ,medicine.disease ,Thalidomide ,Regimen ,Benserazide ,Drug Combinations ,Neoplasms ,medicine ,Humans ,business ,Pantoprazole ,Repurposing ,medicine.drug ,media_common - Abstract
Advances in cancer therapy have yet to impact worldwide cancer mortality. Poor cancer drug affordability is one of the factors limiting mortality burden strikes. Up to now, cancer drug repurposing had no meet expectations concerning drug affordability. The three FDA-approved cancer drugs developed under repurposing -all-trans-retinoic acid, arsenic trioxide, and thalidomide- do not differ in price from other drugs developed under the classical model. Though additional factors affect the whole process from inception to commercialization, the repurposing of widely used, commercially available, and cheap drugs may help. This work reviews the concept of the malignant metabolic phenotype and its exploitation by simultaneously blocking key metabolic processes altered in cancer. We elaborate on a combination called BAPST, which stands for the following drugs and pathways they inhibit: Benserazide (glycolysis), Apomorphine (glutaminolysis), Pantoprazole (Fatty-acid synthesis), Simvastatin (mevalonate pathway), and Trimetazidine (Fatty-acid oxidation). Their respective primary indications are: • Parkinson's disease (benserazide and apomorphine). • Peptic ulcer disease (pantoprazole). • Hypercholesterolemia (simvastatin). • Ischemic heart disease (trimetazidine). When used for their primary indication, the literature review on each of these drugs shows they have a good safety profile and lack predicted pharmacokinetic interaction among them. Most importantly, the inhibitory enzymatic concentrations required for inhibiting their cancer targets enzymes are below the plasma concentrations observed when these drugs are used for their primary indication. Based on that, we propose that the regimen BAPTS merits preclinical testing.
- Published
- 2021
39. Pharmacodynamics of current and emerging treatments for cervical cancer
- Author
-
Alfonso Dueñas-González and Aurora Gonzalez-Fierro
- Subjects
Oncology ,Radiation-Sensitizing Agents ,medicine.medical_specialty ,Immune checkpoint inhibitors ,medicine.medical_treatment ,Uterine Cervical Neoplasms ,Antineoplastic Agents ,Hysterectomy ,Toxicology ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Animals ,Humans ,Medicine ,Neoplasm Staging ,Pharmacology ,Cervical cancer ,Chemotherapy ,business.industry ,Palliative Care ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Locally advanced disease ,Pharmacodynamics ,Female ,business - Abstract
Introduction: Beyond early stages of cervical cancer (1A1, IA2, IB1, IIA1,), locally advanced disease (IB2, IIA2, IIA2, IIB, IIIA, IIIB, IIIC, IVA) and advanced (metastatic, recurrent or pe...
- Published
- 2019
40. Selection of a GPER1 Ligand via Ligand-based Virtual Screening Coupled to Molecular Dynamics Simulations and Its Anti-proliferative Effects on Breast Cancer Cells
- Author
-
Irene Mendoza-Lujambio, Berenice Prestegui-Martel, Manuel Jonathan Fragoso-Vázquez, José Correa-Basurto, Alma Chavez-Blanco, Marlet Martínez-Archundia, Martiniano Bello, José Rubén García-Sánchez, Alberto Martínez-Muñoz, José G. Trujillo-Ferrara, David Méndez-Luna, and Alfonso Dueñas-González
- Subjects
0301 basic medicine ,Cancer Research ,Cell signaling ,In silico ,Drug Evaluation, Preclinical ,Estrogen receptor ,Antineoplastic Agents ,Breast Neoplasms ,Molecular Dynamics Simulation ,Ligands ,Receptors, G-Protein-Coupled ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tumor Cells, Cultured ,Humans ,Benzodioxoles ,Cell Proliferation ,Pharmacology ,Phenol red ,Dose-Response Relationship, Drug ,Molecular Structure ,Chemistry ,Cell growth ,In vitro ,030104 developmental biology ,MCF-7 ,Biochemistry ,Cell culture ,030220 oncology & carcinogenesis ,Quinolines ,Thermodynamics ,Molecular Medicine ,Female ,Drug Screening Assays, Antitumor - Abstract
Background: Recent reports have demonstrated the role of the G Protein-Coupled Estrogen Receptor 1 (GPER1) on the proliferation of breast cancer. The coupling of GPER1 to estrogen triggers cellular signaling pathways related to cell proliferation. Objective: Develop new therapeutic strategies against breast cancer. Method: We performed in silico studies to explore the binding mechanism of a set of G15 /G1 analogue compounds. We included a carboxyl group instead of the acetyl group from G1 to form amides with several moieties to increase affinity on GPER1. The designed ligands were submitted to ligand-based and structure-based virtual screening to get insights into the binding mechanism of the best designed compound and phenol red on GPER1. Results: According to the in silico studies, the best molecule was named G1-PABA ((3aS,4R,9bR)-4-(6- bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-carboxylic acid). It was synthesized and assayed in vitro in breast cancer (MCF-7 and MDA-MB-231) and normal (MCF-10A) cell lines. Experimental studies showed that the target compound was able to decrease cell proliferation, IC50 values of 15.93 µM, 52.92 µM and 32.45 µM in the MCF-7, MDA-MB-231 and MCF-10A cell lines, respectively, after 72 h of treatment. The compound showed better IC50 values without phenol red, suggesting that phenol red interfere with the G1-PABA action at GPER1, as observed through in silico studies, which is present in MCF-7 cells according to PCR studies and explains the cell proliferation effects. Conclusion: Concentration-dependent inhibition of cell proliferation occurred with G1-PABA in the assayed cell lines and could be due to its action on GPER1.
- Published
- 2019
41. Emerging DNA methylation inhibitors for cancer therapy: challenges and prospects
- Author
-
Aurora Gonzalez-Fierro and Alfonso Dueñas-González
- Subjects
Pharmacology ,business.industry ,Azacitidine ,Cancer therapy ,Decitabine ,Drug Discovery ,DNA methylation ,Genetics ,Cancer research ,medicine ,Molecular Medicine ,Epigenetics ,Cancer development ,business ,medicine.drug - Abstract
Introduction: There is evidence of the association of DNA methylation alterations with cancer development and progression.Areas covered: This review will briefly discuss the basis of epigenetics an...
- Published
- 2019
42. Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
- Author
-
Alfonso Dueñas-González, Elizabeth Langley, Alma Chavez-Blanco, José Chanona-Vilchis, Catalina Trejo-Becerril, Enrique Pérez-Cárdenas, Lucia Taja-Chayeb, Alejandro García-Carrancá, and Guadalupe Domínguez-Gómez
- Subjects
0301 basic medicine ,MMP2 ,medicine.drug_class ,OncoTargets and Therapy ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,valproic acid ,medicine ,Gelatinase ,metastasis ,Pharmacology (medical) ,Epigenetics ,ras ,Original Research ,Valproic Acid ,epigenetics ,Chemistry ,Cell growth ,Histone deacetylase inhibitor ,Hydralazine ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,hydralazine ,medicine.drug - Abstract
Enrique Pérez-Cárdenas,1 Lucía Taja-Chayeb,1 Catalina Trejo-Becerril,1 José Chanona-Vilchis,2 Alma Chávez-Blanco,1 Guadalupe Domínguez-Gómez,1 Elizabeth Langley,1 Alejandro García-Carrancá,3,4 Alfonso Dueñas-González3,4 1Division of Basic Research, Instituto Nacional de Cancerología, Mexico City, Mexico; 2Department of Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico; 3Unit of Biomedical Research on Cancer, Biomedical Research Institute, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico; 4Unit of Biomedical Research on Cancer, Instituto Nacional de Cancerologia, Mexico City, Mexico Introduction: Metastasis involves the accumulation of genetic and epigenetic alterations leading to activation of prometastatic genes and inactivation of antimetastatic genes. Among epigenetic alterations, DNA hypermethylation and histone hypoacetylation are the focus of intense translational research because their pharmacological inhibition has been shown to produce antineoplastic activity in a variety of experimental models. Aims: This study aimed to evaluate the antimetastatic effect of the DNA-methylation inhibitor, hydralazine, and the histone deacetylase inhibitor, valproic acid. Methods: NIH 3T3-Ras murine cells were treated with hydralazine and valproic acid to evaluate their effects upon cell proliferation, cell motility, chemotaxis, gelatinase activity, and gene expression. Lung metastases were developed by intravenous injection of NIH 3T3-Ras cells in BALB/c nu/nu mice and then treated with the drug combination. Results: Treatment induced a growth-inhibitory effect on NIH 3T3-Ras cells, showed a trend toward increased gelatinase activity of MMP2 and MMP9, and inhibited chemotaxis and cell motility. The combination led to a strong antimetastatic effect in lungs of nude mice. Conclusion: Hydralazine and valproic acid, two repositioned drugs as epigenetic agents, exhibit antimetastatic effects in vitro and in vivo and hold potential for cancer treatment. Keywords: hydralazine, valproic acid, epigenetics, metastasis, ras
- Published
- 2018
43. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy
- Author
-
Rafael Isaac Ponce-Toledo, Donna Lai, Sheng Hua, Alejandro Schcolnik-Cabrera, Alfonso Dueñas-González, Armando R. Tovar, Alma Chavez-Blanco, Delia Pérez-Montiel, José Díaz-Chávez, Ariana Vargas-Castillo, Nimbe Torres, Guadalupe Domínguez-Gómez, and Mandy Juarez
- Subjects
Indazoles ,Cancer therapy ,Anabolism ,Cell Survival ,Science ,Indomethacin ,Oxidative phosphorylation ,Oxidative Phosphorylation ,Article ,Mice ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,Animals ,Humans ,Insulin ,Glycolysis ,Clonogenic assay ,Orlistat ,Multidisciplinary ,Glutaminolysis ,Chemistry ,Catabolism ,Daunorubicin ,Metabolism ,Cancer metabolism ,Gene Expression Regulation, Neoplastic ,Vincristine ,Growth Hormone ,Colonic Neoplasms ,Cancer cell ,Cancer research ,Medicine ,Mitoxantrone ,Energy Metabolism ,Metabolic Networks and Pathways - Abstract
The malignant energetic demands are satisfied through glycolysis, glutaminolysis and de novo synthesis of fatty acids, while the host curses with a state of catabolism and systemic inflammation. The concurrent inhibition of both, tumor anabolism and host catabolism, and their effect upon tumor growth and whole animal metabolism, have not been evaluated. We aimed to evaluate in colon cancer cells a combination of six agents directed to block the tumor anabolism (orlistat + lonidamine + DON) and the host catabolism (growth hormone + insulin + indomethacin). Treatment reduced cellular viability, clonogenic capacity and cell cycle progression. These effects were associated with decreased glycolysis and oxidative phosphorylation, leading to a quiescent energetic phenotype, and with an aberrant transcriptomic landscape showing dysregulation in multiple metabolic pathways. The in vivo evaluation revealed a significant tumor volume inhibition, without damage to normal tissues. The six-drug combination preserved lean tissue and decreased fat loss, while the energy expenditure got decreased. Finally, a reduction in gene expression associated with thermogenesis was observed. Our findings demonstrate that the simultaneous use of this six-drug combination has anticancer effects by inducing a quiescent energetic phenotype of cultured cancer cells. Besides, the treatment is well-tolerated in mice and reduces whole animal energetic expenditure and fat loss.
- Published
- 2021
44. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
- Author
-
Myrna Candelaria-Hernández, Olga Gutiérrez-Hernández, Mayra Ponce-Martínez, Alejandro Avilés-Salas, David Cantú-de-León, Lucia Taja-Chayeb, Alfonso Dueñas-González, and Luis F. Oñate-Ocaña
- Subjects
Oncology ,medicine.medical_specialty ,EZH2 mutations. Diffuse large B-cell lymphoma. Progression-free survival. Overall survival. Cohort study ,Population ,Cohort Studies ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Enhancer of Zeste Homolog 2 Protein ,Progression-free survival ,education ,education.field_of_study ,business.industry ,Hazard ratio ,General Medicine ,Exons ,medicine.disease ,Prognosis ,RC31-1245 ,Relative risk ,Cohort ,Mutation ,Rituximab ,Lymphoma, Large B-Cell, Diffuse ,Neoplasm Recurrence, Local ,business ,Diffuse large B-cell lymphoma ,medicine.drug ,Cohort study - Abstract
Background Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. Methods In a cohort of patients with DLBCL treated between 2015 and 2017, we analyzed the presence of EZH2 mutations and their association with clinical response (CR), relapse, progression-free survival (PFS), and overall survival (OS). Results A total of 198 patients were included; of them, 30 (15.2%) had mutations at codon 641, in exon 16 of EZH2. Response was achieved in 151 patients (76.3%), and 43 (21.7%) relapsed or progressed during follow-up. EZH2 mutations were associated with relapse/progression (risk ratio [RR] 1.18; 95% confidence interval [CI] 0.98-1.42; p = 0.031), while a trend for not achieving a complete response was observed (RR: 0.876; 95%CI 0.74-1.038; p = 0.071). Of note, Tyr641His and Tyr641Ser EZH2 mutations were associated with shorter PFS (hazard ratio 3.234; 95% CI 1.149-9.1; p = 0.026). Conclusion The presence of EZH2 mutations was negatively associated with relapse/progression and showed a trend for lack of complete response. Further studies are needed to define better the prognostic significance of these mutations in Mexican-Mestizo DLBCL patients.
- Published
- 2021
45. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
- Author
-
Alfonso Dueñas-González and Myrna Candelaria
- Subjects
Oncology ,medicine.medical_specialty ,Standard of care ,diffuse large B-cell lymphoma ,non-Hodgkin lymphoma treatment ,Review ,03 medical and health sciences ,0302 clinical medicine ,Chemoimmunotherapy ,Prednisone ,immune system diseases ,Internal medicine ,hemic and lymphatic diseases ,Medicine ,rituximab biosimilars ,Cyclophosphamide/doxorubicin/vincristine ,business.industry ,lcsh:RC633-647.5 ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,Lymphoma ,Regimen ,R-CHOP ,chemoimmunotherapy ,030220 oncology & carcinogenesis ,Rituximab ,business ,Diffuse large B-cell lymphoma ,030215 immunology ,medicine.drug - Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin lymphoma worldwide. The current standard of care is chemoimmunotherapy with an R-CHOP regimen. We aim to review the role of this regimen after two decades of being the standard of care. Methods: A comprehensive literature review of DLBCL, including the epidemiology, trials defining R-CHOP as the standard of care, as well as dose intensification and dose reduction schemes. Additionally, we briefly review the development of rituximab biosimilars and the addition of targeted drugs to R-CHOP in clinical trials. Discussion: R-CHOP cures approximately 70% of DLBCL patients. Dose-dense regimens do not show a benefit in response and increase toxicity. Dose reduction, particularly in elderly patients or with comorbidities, may be a treatment option. DLBCL constitutes a group of diseases that activate different biological pathways. Matching specific treatments to a defined genetic alteration is under development. Rituximab biosimilars have become available to a broader population, particularly in developing countries, where access to treatment is limited because of economic resources. Conclusion: DLBCL landscape is heterogeneous. R-CHOP immunochemotherapy has been a standard of care for two decades and cures approximately 70% of cases. Molecular characterization of patients is evolving and may have critical therapeutic implications.
- Published
- 2021
46. In Vivo Rat Model to Study Horizontal Tumor Progression
- Author
-
Trejo-Becerril, Catalina, primary, Pérez-Cárdenas, Enrique, additional, and Dueñas-González, Alfonso, additional
- Published
- 2014
- Full Text
- View/download PDF
47. Late-Onset Hematological Toxicity (LOHT) in Patients with B-Cell Lymphomas: A Survey in 758 Cases
- Author
-
Palacios-Campos, Adriana, primary, Dueñas-González, Alfonso, additional, Gutiérrez-Hernández, Olga, additional, and Candelaria-Hernández, Myrna, additional
- Published
- 2021
- Full Text
- View/download PDF
48. The role of extracellular DNA (exDNA) in cellular processes
- Author
-
Fernández-Domínguez, Ileana J., primary, Manzo-Merino, Joaquin, additional, Taja-Chayeb, Lucia, additional, Dueñas-González, Alfonso, additional, Pérez-Cárdenas, Enrique, additional, and Trejo-Becerril, Catalina, additional
- Published
- 2021
- Full Text
- View/download PDF
49. IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER
- Author
-
Guadalupe E Trejo-Durán, Lucely Cetina-Pérez, Elva G Vanoye-Carlo, Leonardo S Lino-Silva, Cristina Alvarado-Silva, Tatiana Galicia-Carmona, Roberto Jiménez-Lima, Omar H Castañeda-Renderos, Eder Arango-Bravo, Celia Flores-de la Torre, and Alfonso Dueñas-González
- Subjects
Oncology ,medicine.medical_specialty ,Bevacizumab ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Uterine Cervical Neoplasms ,Disease ,Pembrolizumab ,B7-H1 Antigen ,Internal medicine ,medicine ,Humans ,Cervical cancer ,Chemotherapy ,Clinical Trials as Topic ,business.industry ,General Medicine ,Immunotherapy ,medicine.disease ,Clinical trial ,Female ,Nivolumab ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
Cervical cancer (CC) is one of the most common gynecological tumors and an important health problem, especially in developing countries. The vast majority of patients in early stages are cured of the disease with surgical treatment and with concomitant chemoradiotherapy in locally advanced stages. However, in patients with recurrent, persistent, or metastatic cervical CC, the effectiveness of treatment is limited, except for the combination of chemotherapy based on platinum doublets plus bevacizumab, the treatment that has achieved the best results to date. Programmed cell death-1/PD ligand-1 (PD-1/PD-L1) inhibitors could be a novel and cutting-edge therapeutic option to improve clinical outcomes in this group of patients. Thus far, there are a few Phase I/II clinical trials that have assessed the usefulness of pembrolizumab and nivolumab in this group of patients; these include the KEYNOTE 028, KEYNOTE 158, and CHECKMATE 358 trials, in which clinical benefit has been proven with PD-1/PD-L1 inhibitors in recurrent, persistent, or metastatic CC, as second-line treatment. There are also some ongoing trials that could provide further evidence on the PD-1/PD-L1 pathway as a therapeutic target in CC. In this review, we will focus on the usefulness of these PD-1/PDL1 inhibitors in CC, as well as on trials that are still in the recruitment phase, to confirm their effectiveness in this clinical setting.
- Published
- 2020
50. Late-Onset Hematological Toxicity (LOHT) in Patients with B-Cell Lymphomas: A Survey in 758 Cases
- Author
-
Adriana Palacios-Campos, Alfonso Dueñas-González, Myrna Candelaria-Hernández, and Olga Gutiérrez-Hernández
- Subjects
Cytopenia ,medicine.medical_specialty ,Multivariate analysis ,business.industry ,Late onset ,General Medicine ,medicine.disease ,Lymphoma ,Myeloid Neoplasm ,medicine.anatomical_structure ,Hematological toxicity ,hemic and lymphatic diseases ,Internal medicine ,Medicine ,In patient ,business ,B cell - Abstract
Background The increasing survival of patients with non-Hodgkin lymphoma has allowed the diagnosis of long-term com- plications, including late-onset hematological toxicity (LOHT), transitory cytopenias, or therapy-related myeloid neoplasm (t-MDS/t-AML). Objective The objective of the study was to determine the frequency and clinical evolution of LOHT in patients with lymphoproliferative malignancies. Materials and methods Two cohorts of patients B-cell lymphomas were reviewed. Patients who achieved full hematologic recovery at the end of treatment, and thereafter developed any degree of cytopenia were included in the study. Clinical and biochemical parameters were compared between patients with and without cytopenias with X2 test. Bi-and multivariate analyses were performed to evaluate factors associated with the development of late-onset cytopenias. Results Of 758 patients enrolled, 19 developed cytopenias (2.5%). Transitory cytopenia was documented in 6 cases, 3 developed ICUS, 8 t-MDS, and 2 t-AML. In patients with FL, only hemoglobin 6 nodal areas (p = 0.037) at diagnosis were factors statistically significant for the development of cytopenia. During cytopenias, 55% of patients died. Conclusions LOHT constitutes a cause of morbidity and mortality in 2.5% of lymphoma patients treated with different therapy regimens.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.